The agreement includes process development, scale-up and manufacturing for pre-clinical studies.
OctoPlus evaluated the feasibility of a controlled release formulation that combines a proprietary eye care ingredient of ESBATech with PolyActive.
OctoPlus CEO Jan Egberts said he is delighted to see the success of the technology further validated in a product from ESBATech.
"In addition to Locteron, this programme is now next in line in the commercialisation of the PolyActive controlled release technology," Egberts said.